These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35885065)

  • 1. Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells.
    Pęksa R; Kunc M; Czapiewski P; Piątek M; Hać S; Radecka B; Biernat W
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.
    Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4131-4139. PubMed ID: 36042047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 4. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
    Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
    Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
    Pęksa R; Kunc M; Popęda M; Piątek M; Bieńkowski M; Żok J; Starzyńska A; Perdyan A; Sowa M; Duchnowska R; Biernat W
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
    Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
    Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.
    Loch FN; Kamphues C; Beyer K; Schineis C; Rayya W; Lauscher JC; Horst D; Dragomir MP; Schallenberg S
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma.
    Zhang Z; Li M; Wang J; Liu M; Chen H; Lou Y; Wang Y; Sun Q; Zhu D; Li P; Bi Y
    Endocr Relat Cancer; 2022 May; 29(7):403-413. PubMed ID: 35521773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of B7 family checkpoint proteins in cervical cancer.
    Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
    Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma.
    Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P
    Urol Oncol; 2022 May; 40(5):200.e1-200.e10. PubMed ID: 35346570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.
    Ilié M; Beaulande M; Ben Hadj S; Chamorey E; Schiappa R; Long-Mira E; Lassalle S; Butori C; Cohen C; Leroy S; Guérin O; Mouroux J; Marquette CH; Pomerol JF; Erb G; Hofman V; Hofman P
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30216999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy.
    Chan AM; Roldan Urgoiti G; Jiang W; Lee S; Kornaga E; Mathen P; Yeung R; Enwere EK; Box A; Konno M; Koebel M; Joseph K; Doll CM
    Front Oncol; 2022; 12():1000263. PubMed ID: 36276142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.
    Lang-Schwarz C; Melcher B; Hartmann A; Bertz S; Dregelies T; Lang-Schwarz K; Vieth M; Sterlacci W
    Int J Colorectal Dis; 2021 Nov; 36(11):2497-2510. PubMed ID: 34170390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma.
    Wang LC; Wang YL; He B; Zheng YJ; Yu HC; Liu ZY; Fan RR; Zan X; Liang RC; Wu ZP; Tang X; Wang GQ; Xu JG; Zhou LX
    Clin Immunol; 2022 Dec; 245():109178. PubMed ID: 36368642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
    Wang Y; Deng J; Wang L; Zhou T; Yang J; Tian Z; Yang J; Chen H; Tang X; Zhao S; Zhou L; Tong A; Xu J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.